195 related articles for article (PubMed ID: 35226138)
1. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
Pfister D; Oechsle K; Schmidt S; Busch J; Bokemeyer C; Heidenreich A; Heinzelbecker J; Ruf C; Winter C; Zengerling F; Kliesch S; Albers P; Oing C
World J Urol; 2022 Dec; 40(12):2853-2861. PubMed ID: 35226138
[TBL] [Abstract][Full Text] [Related]
2. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
3. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
4. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
5. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
6. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.
Urbini M; Bleve S; Schepisi G; Menna C; Gurioli G; Gianni C; De Giorgi U
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069192
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
9. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
Berger LA; Bokemeyer C; Lorch A; Hentrich M; Kopp HG; Gauler TC; Beyer J; de Wit M; Mayer F; Boehlke I; Oing C; Honecker F; Oechsle K
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1211-20. PubMed ID: 24696231
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
12. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
13. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.
Kollmannsberger C; Schleucher N; Rick O; Metzner B; Hartmann JT; Schöffski P; Beyer J; Casper J; Sosada M; Schmoll HJ; Böhlke I; Meisner C; Kanz L; Bokemeyer C
Eur J Cancer; 2003 Apr; 39(6):775-82. PubMed ID: 12651203
[TBL] [Abstract][Full Text] [Related]
14. Late relapse of germ cell tumors after cisplatin-based chemotherapy.
Gerl A; Clemm C; Schmeller N; Hentrich M; Lamerz R; Wilmanns W
Ann Oncol; 1997 Jan; 8(1):41-7. PubMed ID: 9093706
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
17. Intensive and timely chemotherapy, the key of success in testicular cancer.
Fléchon A; Culine S; Droz JP
Crit Rev Oncol Hematol; 2001 Jan; 37(1):35-46. PubMed ID: 11164717
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Kollmannsberger C; Bokemeyer C
Curr Opin Support Palliat Care; 2008 Sep; 2(3):167-72. PubMed ID: 18685416
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
20. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]